
|Videos|June 15, 2016
Considerations When Choosing an Antimalarial
Advertisement
Episodes in this series

Jeff Goad, PharmD, MPH, discusses some things pharmacists should consider when choosing an antimalarial.
Advertisement
Related to this article

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.

An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.

Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.

No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, though HHS maintains the pilot is ongoing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5


















